Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

Potentiation of Chemotherapy in Brain Tumors by Zinc

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT04488783
Recruitment Status : Recruiting
First Posted : July 28, 2020
Last Update Posted : July 28, 2020
Sponsor:
Information provided by (Responsible Party):
Dr. Leor Zach, MD, Sheba Medical Center

Brief Summary:
Glioblastoma (GB) is the most common and aggressive type of primary malignant brain tumor in adults. Despite advances in surgical resection, radiotherapy and chemotherapy, prognosis remains very poor. Temozolomide (TMZ) as an alkylating agent has become part of GBM management but it has contributed only marginally to prolongation of life in GBM patients. Our aim is to evaluate the therapeutic potential of the trace element zinc to facilitate temozolomide tumor cell toxicity in GBM. P53 gene is inactive/mutant in most of these patients which may affect the resistance to apoptosis of tumor cells by chemotherapy. Zinc (Zn) has a crucial role in the biology of p53, in that p53 binds to DNA through a structurally complex domain stabilized by zinc atom. We have shown that the cytotoxic activity of TMZ is substantially increased with the addition of zinc in vitro with GBM cell lines as well as in vivo, with intracranial GBM xenografts. Numerous studies of zinc in animal models and in human subjects support its use in the treatment and possibly the prevention of cancer. Zinc has been consumed by the public as an essential mineral (and thus is category A drug) in concentrations which allows this effect with Temozolomide. Vitamin C could add to this by priming the immune system for lymphocyte- linked cancer killing. The vitamin c increases the number of tumor infiltrating lymphocytes and enhances the activation of the immune system.We propose a single arm phase II clinical trial in 30 newly diagnosed GBM patients who will be treated with the standard chemo-radiotherapy with the addition of zinc and vitamin C.

Condition or disease Intervention/treatment Phase
Newly Diagnosed Glioblastoma Who Underwent at Least Partial Resection of the Tumor Surgically Dietary Supplement: zinc and ascorbate Not Applicable

Detailed Description:
We propose a single arm phase II clinical trial in 30 newly diagnosed GBM patients who will be treated with the standard chemo-radiotherapy with the addition of daily zinc. We will follow the toxicity, Progression free survival and overall survival of this group of patients. We hope to demonstrate the anti-tumor activity of zinc that will enhance the activity of temozolomide chemotherapy in adult glioblastoma patients. We will also follow the safety and monitor quality of life during treatment. In this study, we will compare results of patients receiving zinc to historical patient data. We will review patient portfolios with GB tumors that received treatment as the subjects in this study in the last five years before the study began. Collecting the data and separating the identified data from the file in a way that cannot be retrieved in any way will be done by a staff member from Dr Ruty Shai's laboratory who is authorized to open medical files. We will adjust the age and number of patients in each gender. Data collected: date of birth, age of disease development, gender, data after receiving treatment: Progression free survival and overall survival of this group of patients, side effects, and quality of life.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 30 participants
Allocation: N/A
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: Potentiation of Chemotherapy in Brain Tumors by Zinc
Estimated Study Start Date : July 30, 2020
Estimated Primary Completion Date : July 30, 2022
Estimated Study Completion Date : December 30, 2022

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Brain Tumors

Arm Intervention/treatment
Experimental: Glioblastoma patients
newly diagnosed GB who underwent at least partial resection of the tumor surgically
Dietary Supplement: zinc and ascorbate
oral zinc and ascorbate




Primary Outcome Measures :
  1. progression free survival (PFS) [ Time Frame: year 1 ]
  2. overall survival (OS) [ Time Frame: year 2 ]

Secondary Outcome Measures :
  1. Tcell count [ Time Frame: year 2 ]
    Blood test

  2. Level of Interleukin 6 [ Time Frame: year 2 ]
    Interleukin 6 and Tumor Necrosis Factor quantification

  3. Tumor Necrosis Factor quantification [ Time Frame: year 2 ]
    Blood test



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years to 90 Years   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Males and Females,
  • age ≥ 18 years old,
  • newly diagnosed GBM, Karnofsky performance status of ≥ 70,
  • after partial resection or gross tumor resection (GTR) who recovered from surgical resection.

Exclusion Criteria:

  • GB patients with less than 20% of tumor removed,
  • Prior treatment for GB (other than surgical resection),
  • any known malignancy outside of the brain in the last 5 years,
  • in ability to swallow drugs.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT04488783


Contacts
Layout table for location contacts
Contact: Ruty Shai, PhD 972-543938318 ruty.shai@sheba.health.gov.il

Locations
Layout table for location information
Israel
Sheba Medical Center Recruiting
Ramat Gan, Israel
Contact: Ruty Shai, Ph.D    972543938318    ruty.shai@sheba.health.gov.il   
Principal Investigator: Ruty Shai, Ph.D         
Sponsors and Collaborators
Sheba Medical Center
Layout table for additonal information
Responsible Party: Dr. Leor Zach, MD, MD, Sheba Medical Center
ClinicalTrials.gov Identifier: NCT04488783    
Other Study ID Numbers: 4266-17-SMC
First Posted: July 28, 2020    Key Record Dates
Last Update Posted: July 28, 2020
Last Verified: July 2020
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No
Keywords provided by Dr. Leor Zach, MD, Sheba Medical Center:
GBM
glioblastoma
zinc
vitamin C
Additional relevant MeSH terms:
Layout table for MeSH terms
Glioblastoma
Astrocytoma
Glioma
Neoplasms, Neuroepithelial
Neuroectodermal Tumors
Neoplasms, Germ Cell and Embryonal
Neoplasms by Histologic Type
Neoplasms
Neoplasms, Glandular and Epithelial
Neoplasms, Nerve Tissue